Life Sciences
Destiny Pharma plc
Year
2020
Transaction type Equity Capital Markets & Corporate Broking
Sector Life Sciences
finnCap have raised up to £11.5m for Destiny Pharma plc to fund the acquisition of a novel biotherapeutic asset targeting the prevention of recurrence of C. difficile infection, and enable the completion of Phase III clinical trial preparations.
Follow us
Related News
Impact of June Spending Review on UK equities
June 12, 2025
HealthTech Insights
February 19, 2025
Leveraging the UK’s Healthcare & Life Science Sector
August 19, 2024
AI Strategy and Guidance
July 24, 2024
Update to the QCA Code
July 2, 2024